73 results on '"Hay JW"'
Search Results
2. P63 Impact of COVID-19 on Health-Related Quality-of-Life in the United States, Sweden and Norway: A Cross-Country Comparison Using a Panel Survey
3. The Cost Effectiveness Analysis of PD-1 And PD-L1 Agents Compared with Docetaxel for Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
4. An Evaluation of the Cost-Effectiveness of Reslizumab in Poorly Controlled Eosinophilic Asthma
5. Cost Effectiveness Analysis Of Evolocumab, A PCSK9 Inhibitor, From The US Societal Perspective
6. Management of Asymptomatic Term & Late Preterm Newborns Exposed to Maternal Intrapartum Fever: A Societal Cost Benefit Analysis of the Proposed “Triple I” Algorithm
7. Cost-Effectiveness Analysis of Regorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Cost-Effectiveness Of Rivaroxaban Versus Warfarin For Treatment Of Nonvalvular Atrial Fibrillation In Patients With Worsening Renal Function
9. Cost-Effectiveness Analysis of Regorafenib and Tas-102 In Refractory Metastatic Colorectal Cancer
10. The Cost-Effectiveness of Ustekinumab Compared to Infliximab And Adalimumab in Adult Patients with Moderate-Severe Crohn's Disease (Tnf Naïve Population)
11. Cost Effectiveness of Pembrolizumab and Ipilimumab in Advanced Melanoma
12. Cost-Effectiveness of Trastuzumab in Adult Metastatic Gastric Cancer Patients with an Overexpression of HER2
13. Cost Effectiveness Of Lurasidone, Quetiapine, And Olanzapine Monotherapy In The Treatment Of Bipolar I Disorder Depression
14. Cost-Effectiveness Analysis Of Lurasidone And Olanzapine In The Treatment Of Schizophrenia
15. Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective
16. Understanding What Patients Value And Their Willingness-To-Pay (Wtp) For Hemophilia TherapiesA Discrete Choice Experiment
17. Management Of Spinal Cord Injury-Associated Neuropathic Pain With Pregabalin Is Cost-Effective Over Gabapentin
18. PIH13 FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING FOR BREAST CANCER
19. PHP36 COST EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL CARE IN A MEDICARE DRUG BENEFIT PROGRAM
20. PCV83 ECONOMIC ANALYSIS OF ENDOVASCULAR STENTING FOR PERIPHERAL ARTERIAL DISEASE IN LONG LESIONS OF THE SUPERFICIAL FEMORAL ARTERY
21. PIH18 ANALYSIS OF NECROTIZING ENTEROCOLITIS COSTS AMONG EXTREMELY PRETERM INFANTS FED EXCLUSIVELY HUMAN-MILK BASED DIET VS. HUMAN-MILK FORTIFIED WITH BOVINE-MILK BASED SUPPLEMENTS
22. PUK16 COST-EFFECTIVENESS ANALYSIS IN TREATING OVERACTIVE BLADDER WITH URGE INCONTINENCE IN WOMEN: A COMPARISON BETWEEN OXYBUTYNIN AND TOLTERODINE WITH EXPLORATORY ANALYSIS OF FESOTERODINE
23. PSY34 OBESITY AND HEALTH CARE COSTS AND UTILIZATION IN THE VETERAN AFFAIRS POPULATION
24. PMS20 COST EFFECTIVENESS ANALYSIS OF MANAGING CHRONIC GOUT WITH FEBUOXSTAT (ULORIC) VERSUS ALLOPURINOL (ZYLOPRIM)
25. SB4 DEALING WITH SELECTION BIAS IN NONLINEAR SETTINGS: A CASE OF COMPARATIVE EFFECTIVENESS OF STATIN PLUS FIBRATE COMBINATION THERAPY VERSUS STATIN MONOTHERAPY IN TYPE II DIABETES
26. PMH43 UNINTENDED CONSEQUENCES OF CURRENT ANTIDEPRESSANT USE IN A GERIATRIC POPULATION: THE BURDEN OF SIDE-EFFECTS ON ADHERENCE AND COSTS
27. PMC10 COMPARISON BETWEEN PROPENSITY SCORE AND TRADITIONAL COVARIATE ADJUSTMENT WITH LOGISTIC REGRESSION MODELS IN ESTIMATING THE AVERAGE TREATMENT EFFECTS (ATES): RESULTS FROM MONTE CARLO SIMULATIONS
28. PMH40 UNINTENDED CONSEQUENCES OF CURRENT ANTIDEPRESSANT USE IN A GERIATRIC POPULATION: DRUG-DRUG INTERACTIONS AND THEIR IMPLICATIONS FOR ADHERENCE
29. PIN17 COST EFFECTIVE FOR HPV VACCINE
30. PIN14 USING A DECISION SIMULATION MODELTO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAÏVE HBE-ANTIGEN NEGATIVE CHB PATIENTS IN ITALY WITH ENTECAVIR AND TEN OF OVIR
31. IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM
32. PSY15 COST-EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTTHERAPY BY HEMOGLOBINTARGETS IN CHRONIC KIDNEY DISEASE
33. PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
34. PCN23 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT
35. PMH28 COST-EFFECTIVENESS OF ONCE-DAILY STIMULANT, NON-STIMULANT & COMBINED STIMULANT/BEHAVIORAL THERAPY INTERVENTIONS IN THE TREATMENT OF ADHD IN CHILDREN
36. RS4 ASTHMA COSTS AND UTILIZATION IN A MANAGED CARE ORGANIZATION
37. PIH15 ADJUSTING FORTRIAL QUALITY IN A META-ANALYSIS
38. PMC2 THE EFFECT OF PHARMACIST CONSULTATION ON PATIENT MEDICATION ADHERENCE:AN INSTRUMENTAL VARIABLE APPROACH
39. PIN27 USING DECISION SIMULATION MODEL TO EVALUATE THE COST EFFECTIVENESS OF ENTECAVIR COMPARED TO ADEFOVIR THERAPY IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS:ANALYSES FROM A US PAYER PERSPECTIVE
40. PIN12 THE COST-EFFECTIVENESS ANALYSIS OF ENTECAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB) PATIENTS IN POLAND
41. PIN16 COST-EFFECTIVENESS ANALYSIS OF IMMUNIZATION STRATEGIES FOR THE CONTROL OF MENINGOCOCCAL INFECTIOUS DISEASE
42. PMH5 A COMPARISON OF TREATMENT-EMERGENT DIABETES AMONG ATYPICAL AND TYPICAL ANTIPSYCHOTIC USERS: USING A BIVARIATE PROBIT MODEL
43. PCV22 COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)
44. PCV1 CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE
45. PCN14 COST-EFFECTIVENESS OFTAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER
46. PAR11 COST-EFFECTIVENESS ANALYSIS FOR TREATMENTS IN ANKYLOSING SPONDYLITIS
47. PHM2 ECONOMIC AND QUALITY OF LIFE BURDEN OF HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA
48. PCN8 THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION
49. PCN10 ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN PATIENTS WITH HORMONEREFRACTORY PROSTATE CANCER
50. PCN4 ECONOMIC EVALUATION OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. OTHER IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK BUDGET IMPACT ANALYSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.